Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT
TCRαβ+ Cell Deleted Versus Traditional Haploidentical Hematopoietic Stem Cell Transplantation ：A Single-center, Prospective, Non-randomized Controlled Clinical Study
Sijia Gu
110 participants
May 26, 2024
INTERVENTIONAL
Conditions
Summary
This is a single-center prospective, non-randomized controlled clinical study in China using CliniMACS TCRα/β+ cell depleted stem cell haploidentical donors versus conventional Beijing protocol for haploidentical hematopoietic stem cell transplantation in children.
Eligibility
Inclusion Criteria4
- Age 8 weeks to 18 years
- Children who meet the indicators haploidentical hematopoietic cell transplantation
- No HLA ≥ 9/10 donor or not suitable for this type of donor due to illness
- Informed consent must be signed (by the patient or legal representative)
Exclusion Criteria7
- Liver function abnormalities with bilirubin >2 mg/dL and elevation of transaminases higher than 400 U/L
- Chronic active viral hepatitis
- Ejection fraction <50%
- Respiratory failure necessitating supplemental oxygen
- Patients with a history of psychiatric illness or a condition which could interfere with their ability to understand the requirements of the study
- Patients unwilling or unable to comply with the protocol or unable to give informed consent
- Concurrent severe or uncontrolled infection
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Use the CliniMACS TCRα/β deplete from the mobilized peripheral blood stem cells of haploidentical donor in children
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06423131